Table 1.
Baseline DA dialysate concentrations in the CPu and mPFC of mice
| DA |
|||
|---|---|---|---|
| Groups | Experimental Conditions | CPu | mPFC |
| Vehicle | aCSF + DMSO (a) | 11.7 ± 0.9 (9) | 8.4 ± 1.0 (6) |
| AAV5 | aCSF + DMSO (a) | 11.9 ± 0.7 (7) | 9.6 ± 0.7 (5) |
| Vehicle | aCSF (a) | 10.1 ± 0.8 (13) | 6.25 ± 0.8 (9) |
| AAV5 | aCSF (a) | 13.7 ± 2.2 (12) | 5.02 ± 0.3 (10) |
| Vehicle | aCSF + Nom (a) | 29.0 ± 5.6 (4) | 9.3 ± 1.8 (4) |
| AAV5 | aCSF + Nom (a) | 21.3 ± 5.1 (5) | 7.2 ± 0.7 (5) |
| AAV5 + Vehicle | aCSF + DMSO (b) | 10.1 ± 0.8 (5) | n.e |
| AAV5 + IND-1337-ASO | aCSF + DMSO (b) | 11.2 ± 0.9 (5) | n.e |
| AAV5 + Vehicle | aCSF (b) | 12.2 ± 1.6 (10) | n.e |
| AAV5 + IND-1337-ASO | aCSF (b) | 14.8 ± 1.4 (10) | n.e |
| Vehicle | aCSF + Nom (b) | 25.8 ± 4.9 (6) | n.e |
| AAV5 | aCSF + Nom (b) | 28.3 ± 4.4 (6) | n.e |
Extracellular DA levels are expressed as fmol/20 min fraction. In the experiments involving the evaluation of veratridine and quinpirole effects on extracellular DA levels, dimethyl-sulfoxide (DMSO) or nomifensine (Nom) 10 μM were added in the artificial cerebrospinal fluid (aCSF), respectively. Data are means ± SEM of the number of mice shown in parentheses. (a) Dialysis probe was preparing using the Cuprophan membrane, 6000 Da molecular weight cut-off. (b) Dialysis probes were provided from CMA (ref.; CMAP000083). n.e. not examined.